Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.

The RV144 clinical trial of a prime/boost immunizing regimen using recombinant canary pox (ALVAC-HIV) and two gp120 proteins (AIDSVAX B and E) was previously shown to have a 31.2% efficacy rate. Plasma specimens from vaccine and placebo recipients were used in an extensive set of assays to identify...

Full description

Bibliographic Details
Main Authors:	Susan Zolla-Pazner, Allan C deCamp, Timothy Cardozo, Nicos Karasavvas, Raphael Gottardo, Constance Williams, Daryl E Morris, Georgia Tomaras, Mangala Rao, Erik Billings, Phillip Berman, Xiaoying Shen, Charla Andrews, Robert J O'Connell, Viseth Ngauy, Sorachai Nitayaphan, Mark de Souza, Bette Korber, Richard Koup, Robert T Bailer, John R Mascola, Abraham Pinter, David Montefiori, Barton F Haynes, Merlin L Robb, Supachai Rerks-Ngarm, Nelson L Michael, Peter B Gilbert, Jerome H Kim
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3547933?pdf=render

Similar Items

Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.
by: Silvia Ratto-Kim, et al.
Published: (2015-01-01)

Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.
by: Punnee Pitisuttithum, et al.
Published: (2011-01-01)

OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial
by: Chiu J, et al.
Published: (2009-10-01)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
by: Francis D, et al.
Published: (2009-10-01)

IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees
by: Stephanie Fischinger, et al.
Published: (2020-11-01)

P15-14. Assuring data quality of the phase III vaccine trial of ALVAC vaccine priming and AIDSVAX vaccine boosting in Thailand
by: Kunasol P, et al.
Published: (2009-10-01)

La vacunación con ALVAC y AIDSVAX no mostró niveles adecuados de protección para prevenir la infección por VIH
by: Mara Huberman
Published: (2010-07-01)

Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees.
by: Ickwon Choi, et al.
Published: (2015-04-01)

Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees
by: Choi, Ickwon, et al.
Published: (2015)

V1/V2-directed antibodies elicited in RV144 vaccinees bind to a structurally polymorphic site
by: McLellan JS, et al.
Published: (2012-09-01)

Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.
by: Kristina K Peachman, et al.
Published: (2015-01-01)

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee
by: Nathan I. Nicely, et al.
Published: (2015-07-01)

Adventitious Viral Genomes in Vaccines but Not in Vaccinees
by: Robin A. Weiss
Published: (2001-02-01)

Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate
by: Monica Vaccari, et al.
Published: (2019-05-01)

Antibody responses to V2 loop are induced by CRF01_A E and not Clade B envelopes
by: Karasavvas N, et al.
Published: (2012-09-01)

ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.
by: Luca Schifanella, et al.
Published: (2019-12-01)

Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.
by: Luca Schifanella, et al.
Published: (2020-04-01)

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
by: Gabriele Anichini, et al.
Published: (2021-05-01)

Impact of influenza vaccination in the Netherlands, 2007-2016: Vaccinees consult their general practitioner for clinically diagnosed influenza, acute respiratory infections, and pneumonia more often than non-vaccinees.
by: Saverio Caini, et al.
Published: (2021-01-01)

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
by: Raphael Gottardo, et al.
Published: (2013-01-01)

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses
by: Susan Zolla-Pazner, et al.
Published: (2014-11-01)

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
by: Zoe Moodie, et al.
Published: (2020-05-01)

Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition.
by: Giacomo Gorini, et al.
Published: (2020-03-01)

Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees
by: Jose Mateus, et al.
Published: (2020-11-01)

Ability of History Taking Alone to Identify Early Pregnancies Among Potential Measles Vaccinees
by: Philip B. Mead
Published: (1994-01-01)

RV144-like trial in macaques using ALVAC-SIV & gp120 induces innate immunity and increases the frequency of NK22 & NKG2A+ cells in mucosal tissues
by: Liyanage NP, et al.
Published: (2012-09-01)

P19-51 LB. Improvement of the efficacy of ALVAC-HIV vaccine candidates for humans in non human primates
by: Franchini G
Published: (2009-10-01)

Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees
by: David R. Martinez, et al.
Published: (2020-10-01)

Low rate of seropositivity (IgG) to mumps component in MMR vaccinees in Chennai, south India
by: Jeevan Malaiyan, et al.
Published: (2014-01-01)

Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees
by: Ainai, A., et al.
Published: (2022)

A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.
by: Michael A Eller, et al.
Published: (2011-01-01)

A Systematic, Unbiased Mapping of CD8+ and CD4+ T Cell Epitopes in Yellow Fever Vaccinees
by: Anette Stryhn, et al.
Published: (2020-08-01)

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.
by: Susan Zolla-Pazner, et al.
Published: (2014-01-01)

Immune response to hepatitis B vaccine in a group of vaccinees in the Faculty of Allied Health Sciences of the University of Peradeniya
by: AK Baddevithana, et al.
Published: (2015-04-01)

Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military Populations.
by: Bonnie M Slike, et al.
Published: (2017-01-01)

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
by: Siriwat Akapirat, et al.
Published: (2018-01-01)

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand.
by: Punnee Pitisuttithum, et al.
Published: (2015-01-01)

P20-09. Worldwide epitope prevalence of crystallographically resolved anti-V3 antibodies
by: Cardozo TJ, et al.
Published: (2009-10-01)

Immunoprophylaxis against mother-to-child transmission of HIV-1.
by: Miroslaw K Gorny, et al.
Published: (2006-07-01)

Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2
by: Liao L, et al.
Published: (2012-09-01)